

Potential of clove of *Syzygium aromaticum* in development of a therapeutic agent for periodontal disease. A review

SADJ April 2015, Vol 70 no 3 p108 - p115

SJ Pulikkotil¹, S Nath²

SUMMARY

Introduction: Clove (*Syzygium aromaticum*) is a plant-derived spice that has been traditionally used as a natural medicine for the treatment for various ailments including dental diseases.

Aim and objective: To present a comprehensive report on the properties of clove based on an analysis of contemporary scientific and professional literature in order to explore the prospects for its application in the treatment of plaque-induced periodontal diseases.

Methods: An online search was performed in PubMed and Google Scholar using a combination of key words which included clove buds, clove essential oil, eugenol, *Eugenia caryophyllata*, spices, medicinal plant, chemical composition, biological effect, therapeutic use, anti-bacterial, anti-fungal, anti-viral, anti-oxidant, anti-inflammatory, anaesthetic, periodontal, dental, and periodontitis.

Results: *In vitro* studies have shown *Syzygium aromaticum* to have bacteriostatic, bactericidal, anti-viral, anti-mycotic, anti-oxidant, anti-carcinogenic, anaesthetic and analgesic properties. Clove oil has a specific anti-inflammatory property as it inhibits the cyclo-oxygenase-2 and lipo-oxygenase enzymes.

Conclusion: Clove and its derivatives have a definite potential to be used as specific anti-plaque and anti-inflammatory agents for the treatment of periodontal disease. Future research should concentrate on designing new formulations based on clove derivatives in the form of local drug delivery system or topical agents for the treatment of periodontal diseases.

Keywords: *Syzygium aromaticum*; periodontitis; biofilm; non-surgical periodontal therapy

1. **SJ Pulikkotil:** Senior Lecturer, Department of Clinical Dentistry, School of Dentistry, International Medical University, Kuala Lumpur, Malaysia.

2. **S Nath:** Senior Lecturer, Department of Periodontology, Vananchal Dental College, and Hospital, Farathiya, Garhwa, Jharkhand, India.

Corresponding author

SJ Pulikkotil:

International Medical University, School of Dentistry, Kuala Lumpur, Malaysia 57000. Fax number: +603 8656 7229.
Email: Shaju_Jacob@imu.edu.my

ACRONYMS

BHT:	butylated hydroxyl toluene
DPPH:	diphenyl-p-picryl hydrazyl
FRAP:	ferric reducing/ antioxidant power
LPO:	LOX-catalysed lipid peroxidation
MIC:	minimum inhibitory concentration
ROS:	reactive oxygen species

INTRODUCTION

Periodontitis is a multifactorial inflammatory disease process that leads to the destruction of the tissues supporting the teeth.¹ The presence of bacterial plaque is the main etiologic factor involved in the initiation and progression of periodontitis and is related to gingival crevice colonization by microorganisms such as *Aggregatibacter actinomycetemcomitans*, *Porphyromonas gingivalis*, *Prevotella intermedia*, *Tannerella forsythia*, and *Treponema denticola*.^{1,2} These bacteria elicit an immune response that results in periodontal breakdown, causing destruction of soft tissues and bone. The primary goal of periodontal therapy is to remove periodontal pathogens by providing patients with adequate oral hygiene methods combined with professional mechanical plaque control.³ However, this conventional treatment strategy is not always successful and the addition of chemical agents as an adjunct has been suggested to enhance efficacy in achieving better oral health.⁴ Another line of treatment involves modulating the host responses.⁵ Chemotherapeutic agents have been used commonly as adjuncts but increasing incidence of failure and the development of resistance to conventional antibiotics has led to the screening of several medicinal plants for their potential antimicrobial activity and host modulating effects.⁶

Down the ages natural products such as essential oils and other extracts of plants have evoked interest in their possible application in the treatment of oral diseases.⁷⁻⁹ Natural plant products represent a significant source of substances for managing plaque-related diseases such as gingivitis and periodontitis.^{8,9} The World Health Organization observed that the use of traditional medicine for pri-

NEW!

3X BETTER PROTECTION

VS. LEADING TOOTHPASTE*

Enamel Cavities Sensitivity

Gum Plaque Halitosis



THE NEW STANDARD IN TOOTHPASTE



*against acid erosion

continuing the care that starts in your chair



mary healthcare is more popular in many populations than hospital-based conventional care.¹⁰ Many spices possess medicinal properties and their use in traditional systems of medicine has been on record for a long time.¹¹

Clove is a spice obtained from the dried flower bud of the clove tree, *Eugenia caryophyllata* Thunb. (syn. *Syzygium aromaticum*, *Eugenia aromaticum*, Family: *Myrtaceae*).¹¹ Clove has a nail-like appearance and is known by different names in different languages, such as Dutch (nagel), Spanish (clavo) and Portuguese (cravo). They vary in length from about ½ to ¾ inch and contain 14-20% essential oil.¹¹ Clove oil is extracted from the buds, leaves or stems of the tree *Syzygium aromaticum* by steam or water distillation. Traditionally clove leaf oil has been used to treat burns and cuts and even in dental care for alleviating tooth ache and infection.¹² Clove has been shown to be effective against bacteria associated with dental caries and periodontal disease as well as against a large number of other bacteria.¹³ In addition, studies have reported anti-fungal, anti-carcinogenic, anti-allergic and anti-mutagenic activity of *Syzygium aromaticum*.^{12,14} Eugenol, the primary component of clove oil, displays antioxidant and anti-inflammatory properties.^{11,15} The aim of this review is to explore the pharmacological effects of clove and its active components in order to identify the potential for the development of a therapeutic agent in treating periodontal disease.

SEARCH STRATEGY

MEDLINE/PubMed (National Library of Medicine, Bethesda, Maryland) and Google-Scholar was searched for appropriate articles using the following keywords in various combinations: "clove", "*Syzygium aromaticum*", "eugenol", "clove essential oil", "*Eugenia caryophyllata*", "spices", "medicinal plant", "herbal medicine" "chemical composition", "biological effect", "therapeutic use", "antioxidant", "anti-inflammatory", "anti-bacterial", "anti-viral", "anti-mycotic". "periodontal", "periodontitis" and "dental". All articles on human, animal, *in vitro* and *in vivo* studies and reviews published in English were selected. Preference was given to articles that described the composition, pharmacological effects and toxicity of clove. Titles and abstracts of articles that satisfied the eligibility criteria were screened and checked for agreement. The full text of the articles judged by title and abstract to be relevant were read and independently assessed by two reviewers (SJP and SN).

HISTORY OF SYZYGIUM AROMATICUM

The West Indies, Madagascar, Tanzania and Zanzibar are major producers of clove. However, Asian countries such as Indonesia, India, Malaysia and Sri Lanka produce clove in greater quantities.¹⁶ Clove has been used as a spice and fragrance for more than 2,000 years in China. Since ancient times clove has been used to treat medical conditions like dyspepsia, acute or chronic gastritis and diarrhoea.^{11,12,14} Clove oil was used medicinally in France for the first time (1640), as a remedy for treating toothache and was documented in 'Practice of Physic'.¹⁷ Kim *et al.*¹⁸ used it for the treatment of asthma and various allergic disorders by oral administration. In the food industry clove oil or its extract has found use as a flavouring agent in whisky, ice cream, baked goods, candy and mouthwashes.^{12,19} Clove has been used in clinical dentistry in root canal therapy,

surgical dressings, pulp capping agents, cavity liners and in temporary fillings.^{13,20}

COMPONENTS OF CLOVE

Three essential oils are available from clove spices: clove bud oil, clove stem oil and clove leaf oil. Each has a different chemical composition and flavour. The major components of clove oil are eugenol, β -caryophyllene, eugenol acetate and in lesser amounts, benzyl alcohol, chavicol, acetyl salicylate and humulenes.^{14,21} All the active agents which may be extracted are described in Table 1.

Chaieb, Hajlaoui, Zmantar *et al.*¹⁴ isolated clove essential oil by hydro-distillation using gas chromatography-mass spectrometry (GC-MS) analysis. The chemical analysis resulted in the identification of 36 components, with a high concentration of eugenol (88.58%), eugenol acetate (5.62%), β -caryophyllene (1.39%), 2-heptanone (0.93%), ethyl hexanoate (0.66%), humulenol (0.27%), α -humulene (0.19%), calacorene (0.11%) and calamenene (0.10%). Eugenol (4-allyl-1-hydroxy-2-methoxybenzene), a phenolic non-nutrient compound, is one of the major components with a molecular weight of 164.20. β -caryophyllene, the other major constituent of clove oil has a molecular weight of 204.35. Similar results were also observed by Lee and Shibamoto.²⁰ The reported proportions of each constituent vary widely. Prashar, Locke and Evans *et al.*²² found the content of eugenol to be 78%, with 13% β -caryophyllene, whereas Pawar and Thaker²³ found that the content of eugenol was 47.64%, with the concentration of benzyl alcohol at 34.10%. Alma, Ertas, Nitz *et al.*²¹

Table 1: Composition and percentage of clove essential oil obtained with GS-MS analysis.

Sno	Compound	Percentage
1.	2-Heptanone	0.93232
2.	Ethyl hexanoate	0.66098
3.	β -Caryophyllene	1.38830
4.	α -Humulene	0.19985
5.	Calamenene	0.10538
6.	Calacorene	0.11437
7.	Eugenol	88.58535
8.	Eugenyl acetate	5.62086
9.	Humulenol	0.27527
10.	α -pinene	0.04
11.	p-cymene	0.01
12.	limonene	0.01
13.	2-Heptyl cetate	0.04
14.	(E)- β -Ocimene	0.33
15.	2-Nonaone	0.02
16.	Lanalool	0.01
17.	Methyl salicylate	0.07
18.	p-Allyl phenol	0.19
19.	A-Copaene	0.10
20.	Δ -Cadinene	0.04
21.	Caryophyllene oxide	0.02

found the composition to include eugenol (87%), eugenol acetate (8.01%) and β -caryophyllene (3.56%).

PHARMACOLOGICAL EFFECTS OF CLOVE

Antibacterial activity

Natural remedies have been used for a long time for the treatment of various bacterial infections. In the recent practice of medicine, the misuse of antibiotics has led to the development of bacterial resistance. Therefore there is a need for identifying novel antibacterial agents against which there is minimal or no bacterial resistance. Studies on clove oil or its extract may contribute to the development of novel antimicrobial agents to offset the effects of resistance to antibiotics. Essential oils have anti-quorum sensing activity which might be important in reducing the virulence and pathogenicity of drug-resistant bacteria.^{24,25} (Quorum sensing is a means of bacterial intercellular communication. Anti-quorum sensing interrupts that process). A combination therapy of clove with antibiotics could be another method of overcoming bacterial resistance.

Several studies have shown the effectiveness of clove against numerous strains of bacteria.²⁶⁻³⁵ Clove oil and eucalyptus oil exhibited antibacterial properties against the most common oral pathogen *S. Mutans*.²⁷⁻²⁹ Cai and Wu¹³ showed preferential growth-inhibition activity of a crude extract of clove against the gram-negative oral pathogens: *Porphyromonas gingivalis*, *Streptococcus mutans*, *Actinomyces viscosus* and *Prevotella intermedia*. Several other studies have confirmed the *in vitro* antibacterial activity of clove against gram negative bacteria like *Escherichia coli*, *Klebsiella pneumonia*, *Pseudomonas aeruginosa*, *Proteus vulgaris*, *Campylobacter jejuni*, and *Salmonella enteritidis*, and gram-positive bacteria like *Bacillus subtilis* and *Staphylococcus aureus*.³⁰⁻³⁵ Duraipandian, Ayyanar and Ignacimuthu.³⁶ observed antibacterial activity against *Bacillus subtilis*, *Staphylococcus epidermidis*, *Enterococcus faecalis*, *Escherichia coli*, *Ervinia sp.*, and *Proteus vulgaris*. Clove oil exhibited antibacterial activity against five strains of *S. epidermidis* (reference strains CIP106510, E13, S27, S23 and S38) which is mainly attributed to the presence of eugenol,¹² extracts of which have shown antibacterial activity against *Salmonella typhi*.³⁷ Clove oils protects against bacterial colonization of the lungs, seen *in vitro* and in mice infected with *Klebsiella pneumoniae*.^{38, 39} Mytle, Anderson, Doyle, *et al.*⁴⁰ reported that the growth rates of *Listeria monocytogenes* strains were significantly reduced by treatment with 1% and 2% clove oil. Furthermore Ogunwande, Olawore, Ekundayo *et al.*⁴¹ found that the essential oil of the fruit exhibited antibacterial activity against *Staphylococcus aureus*, while the leaf oil inhibited the growth of *Bacillus cereus*, with an MIC of 39mg/mL. Hospital-acquired infections are important due to presence of methicillin-resistant *Staphylococcus aureus* (MRSA) and its ability to cause severe soft tissue, bone or implant infections.⁴² Clove proved to be beneficial against *Staphylococcus* strains including MRSA and *Streptococcus* strains.^{43,44} The antibacterial property of clove is due to the damaging effect it has on the bacterial cell membrane.³⁷

Several authors have investigated the synergistic interaction of clove oil molecule together with a conventional antibiotic.⁴⁵⁻⁴⁷ Time - kill studies have been used to evaluate

the effect of interaction between eugenol together with ampicillin and with gentamicin. The hydrophilic antibiotics such as vancomycin and β -lactam antibiotics have a marginal activity on gram negative bacteria but exhibit enhanced antibacterial activity when pre-treated with eugenol.^{12,46} This synergistic effect could be explained by the fact that eugenol is able to damage the membrane of bacteria allowing increased penetration of vancomycin and β -lactam antibiotics and therefore effecting a greater antimicrobial effect.⁴⁶ In a recent study Moon, Kim and Cha⁴⁵ assessed the inhibitory effects of a combination of eugenol and antibiotics on cariogenic and periodonto-pathogenic bacteria. Although eugenol is effective against both gram-positive and gram-negative microorganisms, contrasting results were found in other studies.^{48,49} Clove was found to be less effective when compared with cinnamon oil.⁴⁹

No clinical studies were identified which had evaluated the effect of eugenol or any of clove extracts on periodonto-pathogenic microorganism.

Anti- Inflammatory activity

Bacteria are responsible for the initiation of periodontal disease, but it is the host immune-inflammatory response which is responsible for the progression of the disease and destruction of the periodontal attachment. One of the pathways is through the synthesis and release of prostaglandin and other arachidonic acid metabolites locally within the periodontal tissue. Tissue damage leads to the production of free arachidonic acid, which is further metabolized via either the cyclooxygenase (COX) pathway to the prostaglandin (PGE₂), prostacyclin and thromboxane or the lipoxygenase (LOX) pathway to the leukotrienes. Therefore it is recognised that potential COX and leukotrienes inhibitors be considered as anti-inflammatory agents.

Few authors have investigated eugenol and acetyl eugenol for potential anti-inflammatory action on COX-2 and LOX enzymes.^{50,51} Eugenol appeared to directly inhibit COX-2 enzyme activity, possibly through complete inhibition of PGE₂, suppression of the nuclear factor kappa B (NF- κ B) pathway and inhibition of interleukin (IL) - 6 production.⁵² Bachlega, de Sousa, Bastos *et al.*⁵³ demonstrated immune-modulatory and anti-inflammatory effects of clove, as it inhibited production of IL-1 β , IL-6 and IL-10. Likewise, Thompson and Eling⁵⁴ demonstrated that eugenol inhibited prostaglandin H synthase activity. Similarly Raghavendra, Diwakr, Lokesh *et al.*⁵⁵ observed in human polymorphonuclear leucocytes that eugenol effectively inhibited the LOX enzyme in a non-competitive nature. Naidu⁵⁶ demonstrated concentration-dependent inhibition of LOX-catalysed lipid peroxidation (LPO) by eugenol. Though no clinical studies have been done, Koh, Murakami, Tanaka *et al.*⁵⁷ found that eugenol exhibits potent anti-inflammatory effects on cultured human gingival fibroblasts.

Antioxidant property

The reactive oxygen species (ROS) produced by our body are responsible for tissue damage and cell death and can inhibit normal function of cellular lipids, proteins, DNA and RNA. This can lead to many chronic diseases such as heart disease, cancer and even periodontitis.⁵⁸ Clove has been identified as a potent anti-oxidant. Antioxidant activity of clove might be due to the higher concentration of phenolic compounds such as eugenol (71.56%), eugenol acetate

(8.99 %) and thymol.^{59,60} The antioxidant activity of clove extract was comparable to that of the natural antioxidant, α -tocopherol (vitamin E) and butylated hydroxyl toluene (BHT).^{20,61,62} *Syzygium aromaticum* derivatives can prevent injury by ROS by scavenging free radicals, by chelation of transition metal ions, by inhibition of oxidant enzymes or by regeneration of α -tocopherol from α -tocopheroxyl radical.^{12,14,59,60}

The anti-oxidant capacity of clove was present when measured by the metal chelating activity, by bleomycin dependant DNA oxidation, by diphenyl-p-picryl hydrazyl (DPPH) radical scavenging activity and by the ferric reducing antioxidant power (FRAP).^{59,60} *Syzygium aromaticum* showed the highest antioxidant activity among 19 different extracts from Thai medicinal plants.⁶³ Cloves showed the highest DPPH radical scavenging activity (90%), highest FRAP values, high metal chelation ability and DNA oxidation among different spices.^{59,60} Clove also showed increased ability to inhibit metal-ion induced LPO.^{59,60} Some of the earlier *in vitro* studies have demonstrated that flavonoids can scavenge O₂, OH and peroxyl radicals, and inhibit LPO in different systems.⁶⁴⁻⁶⁶ High DPPH scavenging activity as well as O₂ radical scavenging activity and metal chelating activity may be responsible for the marked antioxidant action of cloves. Thus the antioxidant properties of spices may be attributed to various mechanisms, which include prevention of chain initiation, chelation of transition metal ion catalysts, decomposition of peroxides, prevention of continued hydrogen abstraction, reductive capacity and radical scavenging activity.⁵⁹

The effect of eugenol is concentration dependant. At low concentrations it has anti-oxidant and anti-inflammatory effects, whereas at high concentrations it acts as a pro-oxidant, leading to tissue damage resulting from the enhanced generation of free radicals.^{12,60} Clove exhibited a higher bleomycin-dependent DNA oxidation activity indicating a pro-oxidant effect.⁶⁰ Clove oil thus shows a powerful antioxidant activity, and can be used as an easily accessible source of natural antioxidants in pharmaceutical applications. No direct studies on periodontal cells or markers have been done to elucidate the effect of clove extracts as an anti-oxidant.

Antifungal activity

Clove possesses fungicidal characteristics *in vitro* and *in vivo* due to its phenolic components, carvacrol and eugenol.^{67,68} The potential drawback in the treatment of fungal diseases is the possibility of the development of antimicrobial resistance. Combination therapy with clove could form an alternative treatment method especially in treating fluconazole-resistant or multi-drug resistant fungal diseases. Studies have shown synergistic interaction with the use of eugenol and/or methyl-eugenol or either in combination with fluconazole or amphotericin B.⁶⁹

Antifungal activity has been seen against *Candida albicans* and *Trichophyton mentagrophytes*,^{70,71} *Onychomycosis*,⁷²

Table 2: Pharmacological effects of clove for dental application.

Activity studied	Effect	Reference
Antibacterial	• Effective against gram positive and gram negative bacteria.	13, 26-29
Anti-inflammatory	• Cytokine inhibition • Suppression of the NF- κ B pathway	50-53
Antioxidant	• Suppresses LPO • Reactive oxygen scavenging activity • DPPH scavenging activity • Hydroxyl radical scavenging activity	59-62
Antifungal	• Effective against <i>Candida albicans</i>	68-70, 77, 79
Antiviral	• Effective against HSV 1 and HSV 2	80, 81
Analgesics	• Anti-nociceptive effect	83-85
Anaesthetic	• Local anaesthesia	86-88

Saccharomyces cerevisiae,⁷³ *E. Caryophyllata*⁷⁴ and *Aspergillus niger*.⁷⁵ The antifungal activity is due to considerable reduction in the quantity of ergosterol, a specific fungal cell membrane component.⁷⁶ Eugenol displayed *in vitro* activity against *C. albicans* cells within biofilms.⁷⁷ Garg and Singh⁷⁸ conducted an experiment using eugenol-loaded lipid nanoparticles in immunosuppressed rats and showed significant improvements in the eugenol-treated site. Similarly eugenol exhibited the minimum inhibitory concentration (MIC) ranging from 0.06 to 0.25% (v/v) and minimum concentration of drug that inhibited 50% of the isolates (defined as MIC50) ranging from 0.06 to 0.12% (v/v) when tested against 38 strains of *Candida* species from denture wearers and 10 collection strains.⁷⁹

Antiviral activity

Viruses are highly sensitive to the components of essential oils. The antiviral activity of eugenol has been tested against the herpes simplex-1 (HSV-1) and HSV-2 viruses.^{80,81} Hussein, Miyashiro, Nakamura et al.⁸² found that *Syzygium aromaticum* extract was highly active at inhibiting replication of the hepatitis C virus. Synergistic interaction between acyclovir and eugenol combination has been seen.

Analgesic activity

For many ages eugenol has been used as a natural remedy for relieving tooth pain. Similarly this technique in modern dental practice has been adopted by many clinicians, in which eugenol can act as an analgesic agent. Eugenol exhibited an analgesic effect in different experimental pain models in mice.^{83,84} Kurian and co-workers⁸⁴ studied the anti-nociceptive ability of eugenol (100mg/kg) in several mouse models and found that the effect was more pronounced in the inflammatory phase than the neurogenic phase. Eugenol can, however, alleviate neuropathic pain.⁸⁴ Guenette, Beaudry, Marier et al.⁸⁵ in their study in male Sprague-Dawley rats, showed that eugenol, at a dose of 40mg/kg, was capable of prolonging reaction time to thermal stimuli. All these results suggested the possible use of eugenol as an analgesic agent.

Anaesthetic activity

Eugenol is cheap and is an easily available topical anaesthetic. It is relatively user-friendly and can be used effectively in lower concentrations than other local anaesthetics.⁸⁶ It is rapidly metabolized and excreted, thus requiring no withdrawal period.⁸⁷ Eugenol shows good anaesthetic effects on inflamed pulpal tissues.⁸⁸

OTHER ACTIVITY OF SYZYGIVM AROMATICUM

Anti-tumour activity

Clove essential oil has been reported to show anti-carcinogenic and anti-mutagenic potential.¹² To overcome the toxic effects of synthetic drugs, clove essential oil can be used to inhibit, delay, block, or reverse the initiation of and promotional events associated with carcinogenesis. Sesquiterpenes found in *Syzygium aromaticum* were investigated as potential anticarcinogenic agents.¹¹ Volatile oils display cytotoxic action towards the human tumour cell lines PC-3 and Hep G2 50.¹⁴ A derivative of eugenol, dihydro-eugenol, has been shown to induce apoptosis of human cancer cells.¹⁴ Studies have demonstrated that eugenol provides protection from chemically induced skin cancer.⁸⁹

Cardiovascular activity

The consumption of polyphenol-rich foods like clove can lower the risks for cardiovascular disease, arterial sclerosis and other disease related to oxidative stress.⁹⁰⁻⁹² Eugenol produces dose-dependent, reversible vasodilator responses, negative inotropic effects in heart muscle, hypotensive effects and smooth muscle relaxant effect.⁹³⁻⁹⁵

POTENTIAL OF CLOVE (SYZYGIVM AROMATICUM) FOR TREATMENT OF PERIODONTAL DISEASE

Periodontal disease initiation and progression occurs as a consequence of the host response to microorganisms present in dental biofilm.^{1,2} The pathogens stimulate the host response resulting in the release of harmful by-products such as cytokines and prostaglandins by leukocytes, fibroblasts or other host tissue-derived cells and enzymes. These break down extracellular matrix components, such as collagen, as well as host cell membranes, consequently leading to periodontal attachment loss and bone resorption.²

Host modulation therapeutic strategies are aimed at inhibition of the progression of inflammatory bone loss associated with periodontitis.⁵ Although a range of biological and pharmacological activities of clove have been reported, there has been a lack of research into its therapeutic potential for destructive periodontal disease. Table 2 describes the therapeutic use of clove for dental application.

Clove exhibited antibacterial activity against gram-negative anaerobic periodontal pathogens, including *Porphyromonas gingivalis* and *Prevotella intermedia*.¹³ Clove may reduce periodontal inflammation by modulation of the signalling pathway (NF-κB) and suppression of IL-6, COX-2 and TNF-α.⁵²⁻⁵⁵ Besides its anti-inflammatory properties, clove also has antioxidant property^{59,60,62} It has an important property for reducing the oxidative stress which is often seen in periodontal disease. It promotes DPPH scavenging activity, hydroxyl radical scavenging and inhibits lipid peroxidation.⁵⁹⁻⁶² It exhibits antifungal activity against *Candida albicans*^{68-70,77} and antiviral activity against Herpes Simplex virus (HSV) 1 and 2.^{80,81} Analgesic⁸³⁻⁸⁵ and anaesthetic properties⁸⁷ of clove could be a natural way of performing painless dental and oral procedures. Additionally, Karmarkar, Choudhury, Das *et al.*⁹⁶ observed that dried clove buds rich in eugenol and eugenol derivative were effective in preventing bone loss and this property would be beneficial for treating periodontal disease.

All these studies demonstrated that therapy with clove and its active components like eugenol can be beneficial for the treatment of periodontal disease as a natural anti-plaque or anti-gingivitis agent. Research has been particularly lacking in the areas of periodontal disease control. Clove can be effectively incorporated in therapeutic agents formulated against periodontal diseases in the form of mouthwashes, tooth pastes, topical agents and local drug delivery devices.

CYTOTOXICITY OF CLOVE

Clove oil and its components are generally recognized as 'safe', but the *in vitro* study by Prashar *et al.*²² demonstrated cytotoxic properties of both the oil and eugenol towards human fibroblasts and endothelial cells. The cytotoxicity may be a function of more than one component. Clove oil was found to be highly cytotoxic at concentrations as low as 0.03% (v/v) with up to 78% of this effect attributable to eugenol and phenolic terpene.²² The second component β-caryophyllene did not contribute towards cytotoxicity. Localised irritation of the skin, ulcer formation, allergic contact dermatitis, tissue necrosis, reduced healing and in rare cases even anaphylactic-like shock are some of the observed reactions when using dental products containing eugenol.⁹⁷ Hartnoll, Moore and Douek¹⁷ reported severe side effects after clove oil ingestion such as hepatotoxicity, generalized seizures and disseminated intravascular coagulopathy. Further research is still required to clearly define the cytotoxic effects of clove.

CONCLUSION

Clove has many properties which have been identified in both basic and specific disease-targeted research that could be of benefit in the treatment of periodontal disease. Yet the review shows glaring gaps in research which is specific to inflammatory periodontal disease. Eugenol, an important constituent of clove, has important anti-microbial and anti-inflammatory properties which could be harnessed and designed for the control and cure of periodontal disease. The fast developing fields of pharmaceutical and nano-technology are bound to impact on the designing of eugenol/clove extract formulations. There are opportunities wherein specific cell or tissue-targeting technology could effectively deliver the natural remedies in appropriate quantities and form. This will also negate the few cytotoxic properties of these compounds. Concerted effort is needed, as revealed by this review, to initiate investigations which could bring the findings hidden on the research benches to effective clinical use. Interdisciplinary research especially between pharmacy and clinical periodontics is seriously advocated. This paper suggests that there will be merit in the return to natural medicine for the treatment of periodontal diseases.

References

1. Apatzidou DA, Riggio MP, Kinane DF. Quadrant root planing versus same day full mouth root planing II. Microbiological findings. *J Clin Periodontol* 2004; 31:141-8.
2. Haffajee AD, Socransky SS. Microbial etiological agents of destructive periodontal diseases. *Periodontol* 2000 1994; 5:78-111.
3. Apatzidou DA, Kinane DF. Nonsurgical mechanical treatment strategies for periodontal disease. *Dent Clin North Am* 2010; 54:1-12.
4. Bonito AJ, Lux L, Lohr KN. Impact of local adjuncts to scaling and root planing in periodontal disease therapy: a systematic

- review. *J Periodontol* 2005; 76:1227-36.
5. Preshaw PM. Host response modulation in periodontics. *Periodontol* 2000 2008; 48:92-110.
 6. Kumar P, Ansari SH, Ali J. Herbal remedies for the treatment of periodontal disease--a patent review. *Recent Pat Drug Deliv Formul* 2009; 3:221-8.
 7. Newman DJ, Cragg DM. Natural products as sources of new drugs over the last 25 years. *J Nat Prod* 2007; 70:461-77.
 8. DiSilvestro RA, DiSilvestro DJ, DiSilvestro DJ. Pomegranate extract mouth rinsing effects on saliva measures relevant to gingivitis risk. *Phytother Res* 2009; 23:1123-7.
 9. Namiranian H, Serino G. The effect of a toothpaste containing aloe vera on established gingivitis. *Swed Dent J* 2012; 36:179-85.
 10. Surathu N, Kurumathur AV. Traditional therapies in the management of periodontal disease in India and China. *Periodontol* 2000 2011; 56:14-24.
 11. Zheng GQ, Kenney PM, Lam LKT. Sesquiterpenes from clove (*Eugenia caryophyllata*). *J Nat Prod* 1992; 55: 999-1003.
 12. Kamatou GP, Vermaak I, Viljoen AM. Eugenol from the remote Maluku Islands to the international market place: a review of a remarkable and versatile molecule. *Molecules* 2012; 17:6953-8.
 13. Cai L, Wu CD. Compounds from *Syzygium aromaticum* possessing growth inhibitory activity against oral pathogens. *J Nat Prod* 1996; 59:987-90.
 14. Chahieb K, Hajaoui H, Zmantar T, Kahla-Nakbi AB, Rouabhia M, Mahdouani K, Bakhrouf A. The chemical composition and biological activity of clove essential oil, *Eugenia caryophyllata* (*Syzygium aromaticum* L. Myrtaceae): a short review. *Phytother Res* 2007; 21:501-6.
 15. Pramod K, Ansari SH, Ali J. Eugenol: a natural compound with versatile pharmacological actions. *Nat Prod Commun* 2010; 5:1999-2006.
 16. Chomchalow N. Spice production in Asia--An overview. Presented at IBC Asian Spice Markets Conference, Singapore, 27-28 May 1996.
 17. Hartnoll G, Moore D, Douek D. Near fatal ingestion of oil of cloves. *Arch Dis Child* 1993; 69: 392-3.
 18. Kim HM, Lee EH, Hong SH, Song HJ, Shim MK, Kim SH, et al. Effect of *Syzygium aromaticum* extract on immediate hypersensitivity in rats. *J Ethnopharmacol* 1998; 60: 125-31.
 19. Lee KYM, Patterson A, Piggot JR, Richardson GD. Origins of flavour in whiskies and a revised flavour wheel: A review. *J Inst Brew* 2001; 107: 287-313.
 20. Lee KG, Shibamoto T. Antioxidant property of aroma extract isolated from clove buds (*Syzygium aromaticum* (L.) Merr. Et Perry). *Food Chem* 2002; 74: 443-8.
 21. Alma HA, Ertas M, Nitz S, Kollmannsberger H. Chemical composition and content of essential oil from the bud of cultivated Turkish clove (*Syzygium aromaticum* L.). *BioResources* 2007; 2:265-9.
 22. Prashar A, Locke IC, Evans CS. Cytotoxicity of clove (*Syzygium aromaticum*) oil and its major components to human skin cells. *Cell Prolif* 2006; 39: 241-8.
 23. Pawar VC, Thaker VS. *In vitro* efficacy of 75 essential oils against *Aspergillus niger*. *Mycoses* 2006; 49: 316-23.
 24. Khan MS, Zahin M, Hasan S, Husain FM, Ahmad I. Inhibition of quorum-sensing regulated bacterial functions by plant essential oils with special reference to clove oil. *Lett Appl Microbiol*. 2009; 49:354-60.
 25. Dorman HJ, Deans SG. Antimicrobial agents from plants: antibacterial activity of plant volatile oils. *J Appl Microbiol* 2000; 88:308-16.
 26. Prabuseenivasan S, Jayakumar M, Ignacimuthu S. *In vitro* antibacterial activity of some plant essential oils. *BMC Complement Altern Med* 2006; 6:39-47.
 27. Chaudhari LK, Jawale BA, Sharma S, Sharma H, Kumar CD, Kulkarni PA. Antimicrobial activity of commercially available essential oils against *Streptococcus mutans*. *J Contemp Dent Pract* 2012; 13:71-4.
 28. Rahim ZH, Khan HB. Comparative studies on the effect of crude aqueous (CA) and solvent (CM) extracts of clove on the cariogenic properties of *Streptococcus mutans*. *J Oral Sci* 2006; 48:117-23.
 29. Uju DE, Obioma NP. Anticariogenic potentials of clove, tobacco and bitter kola. *Asian Pac J Trop Med* 2011; 4:814-8.
 30. Burt SA, Reinders RD. Antibacterial activity of selected plant essential oils against *Escherichia coli* O157:H7. *Lett Appl Microbiol* 2003; 36: 162-7.
 31. Feres M, Figueiredo LC, Barreto IM, Coelho MN, Araujo MW, Cortelli SC. *In vitro* antimicrobial activity of plant extracts and propolis in saliva samples of healthy and periodontally-involved subjects. *J Int Acad Periodontol* 2005; 7: 90-6.
 32. Larhsini M, Oumouid L, Lazrek HB, Wataleb S, Bousaid M, Bekkouche K, et al. Antibacterial activity of some Moroccan medicinal plants. *Phytother Res*. 2001; 15:250-2.
 33. Friedman M, Henika PR, Mandrell RE. Bactericidal activities of plant essential oils and some of their isolated constituents against *Campylobacter jejuni*, *Escherichia coli*, *Listeria monocytogenes*, and *Salmonella enterica*. *J Food Prot* 2002; 65: 1545-60.
 34. Magina MD, Dalmarco EM, Wisniewski A Jr, Schionatto EL, Dalmarco JB, Pizzolatti MG, Brighente IM. Chemical composition and antibacterial activity of essential oils of *Eugenia* species. *J Nat Med* 2009; 63:345-50.
 35. Keskin D, Toroglu S. Studies on antimicrobial activities of solvent extracts of different spices. *J Environ Biol* 2011; 32:251-6.
 36. Duraipandian V, Ayyanar M, Ignacimuthu S. Antimicrobial activity of some ethno-medicinal plants used by Paliyar tribe from Tamil Nadu, India. *BMC Complement Altern Med* 2006 17; 6:35-42.
 37. Devi KP, Nisha SA, Sakthivel R, Pandian SK. Eugenol (an essential oil of clove) acts as an antibacterial agent against *Salmonella typhi* by disrupting the cellular membrane. *J Ethnopharmacol* 2010; 130:107-15.
 38. Fabio A, Cermelli C, Fabio G, Nicoletti P, Quaglio P. Screening of the antibacterial effects of a variety of essential oils on microorganisms responsible for respiratory infections. *Phytother Res* 2007; 21:374-7.
 39. Saini A, Sharma S, Chhibber S. Induction of resistance to respiratory tract infection with *Klebsiella pneumoniae* in mice fed on a diet supplemented with tulsi (*Ocimum sanctum*) and clove (*Syzygium aromaticum*) oils. *J Microbiol Immunol Infect* 2009; 42:107-13.
 40. Mytle N, Anderson GL, Doyle MP, Smith MA. Antimicrobial activity of clove (*Syzygium aromaticum*) oil in inhibiting *Listeria monocytogenes* on chicken frankfurters. *Food Control* 2006; 17: 102-7.
 41. Ogunwande IA, Olawore NO, Ekundayo O, Walker TM, Schmidt JM, Setzer WN. Studies on the essential oils composition, antibacterial and cytotoxicity of *Eugenia uniflora* L. *Int J Aromather* 2005; 15: 147-52.
 42. Neely AN, Maley MP. Survival of enterococci and staphylococci on hospital fabrics and plastic. *J Clin Microbiol* 2000; 38: 724-6.
 43. Warnke PH, Becker ST, Podschun R, Sivananthan S, Springer IN, Russo PA, Wiltfang J, Fickenscher H, Sherry E. The battle against multi-resistant strains: Renaissance of antimicrobial essential oils as a promising force to fight hospital-acquired infections. *J Craniomaxillofac Surg* 2009; 37:392-7.
 44. Enzo AP, Susan JS. Antibacterial activity of Australian plant extracts against methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant enterococci (VRE). *J Basic Microbiol* 2002; 42: 444-8.
 45. Moon SE, Kim HY, Cha JD. Synergistic effect between clove oil and its major compounds and antibiotics against oral bacteria. *Arch Oral Biol* 2011; 56:907-16.
 46. Hemaiswarya S, Doble M. Synergistic interaction of eugenol with antibiotics against gram negative bacteria. *Phytomedicine* 2009; 16:997-1005.
 47. Mayaud L, Carricajo A, Zhiri A, Aubert G. Comparison of bacteriostatic and bactericidal activity of 13 essential oils against strains with varying sensitivity to antibiotics. *Lett Appl Microbiol* 2008; 47:167-73.
 48. Pei RS, Zhou F, Ji BP, Xu J. Evaluation of combined antibacterial effects of eugenol, cinnamaldehyde, thymol, and carvacrol against *E. coli* with an improved method. *J Food Sci* 2009; 74:M379-383.
 49. Gupta C, Kumari A, Garg AP, Catanzaro R, Marotta F. Comparative study of cinnamon oil and clove oil on some oral microbiota. *Acta Biomed* 2011; 82:197-9.
 50. d' Avila Farias M, Oliveira PS, Dutra FS, Fernandes TJ, de Pereira CM, de Oliveira SQ, et al. Eugenol derivatives as potential anti-oxidants: is phenolic hydroxyl necessary to obtain an effect? *J Pharm Pharmacol* 2014; 66:733-46.

51. Daniel AN, Sartoretto SM, Schmidt G, Caparroz-Assef SM, Bersani-Amado C.A, Cuman RKN. Anti-inflammatory and antinociceptive activities of eugenol essential oil in experimental animal models. *Rev Bras Farmacogn* 2009; 19: 212-7.
52. Lee YY, Hung SL, Pai SF, Lee YH, Yang SF. Eugenol suppressed the expression of lipopolysaccharide-induced proinflammatory mediators in human macrophages. *J Endod* 2007;33:698-702.
53. Bachiega TF, de Sousa JP, Bastos JK, Sforcin JM. Clove and eugenol in noncytotoxic concentrations exert immunomodulatory/anti-inflammatory action on cytokine production by murine macrophages. *J Pharm Pharmacol* 2012; 64:610-16.
54. Thompson D, Eling T. Mechanism of inhibition of prostaglandin H synthase by eugenol and other phenolic peroxidase substrates. *Mol Pharmacol* 1989; 36:809-17.
55. Raghavenra H, Diwakar BT, Lokesh BR, Naidu KA. Eugenol--the active principle from cloves inhibits 5-lipoxygenase activity and leukotriene-C4 in human PMNL cells. *Prostaglandins Leukot Essent Fatty Acids* 2006; 74:23-7.
56. Naidu KA. Eugenol - an inhibitor of lipoxygenase-dependent lipid peroxidation. *Prostaglandins Leukot Essent Fatty Acids* 1995; 53:381-3.
57. Koh T, Murakami Y, Tanaka S, Machino M, Sakagami H. Re-evaluation of anti-inflammatory potential of eugenol in IL-1 -stimulated gingival fibroblast and pulp cells. *In Vivo* 2013;27:269-73.
58. Nibali L, Donos N. Periodontitis and redox status: a review. *Curr Pharm Des* 2013; 19:2687-297.
59. A.S.Yadav and D. Bhatnagar, Modulatory effect of spice extracts on iron-induced lipid peroxidation in rat liver. *BioFactors* 2007; 29: 147-57.
60. Yadav AS, Bhatnagar D. Free radical scavenging activity, metal chelation and antioxidant power of some of the Indian spices. *Biofactors* 2007;31:219-27.
61. Yoshimura M, Ito H, Miyashita K, Hatano T, Taniguchi S, Amakura Y, Yoshida T. Flavonol glucuronides and C-glucosidic ellagitannins from *Melaleuca squarrosa*. *Phytochemistry* 2008;69:3062-9
62. Jirovetz L, Buchbauer G, Stoilova I, Stoyanova A, Krastanov A, Schmidt E. Chemical composition and antioxidant properties of clove leaf essential oil. *J Agric Food Chem* 2006; 54: 6303-7.
63. Makchuchit S, Itharat A, Tewtrakul S. Antioxidant and nitric oxide inhibition activities of Thai medicinal plants. *J Med Assoc Thai* 2010;93:S227-S235.
64. Gülçin İ. Antioxidant activity of food constituents: an overview. *Arch Toxicol* 2012;86:345-391.
65. Lotito SB, Fraga CG. (+)-Catechin prevents human plasma oxidation. *Free Radic Biol Med* 1998;24:435-41.
66. Morel I, Lescoat G, Cillard P, Cillard J. Role of flavonoids and iron chelation in antioxidant action. *Methods Enzymol* 1994;234:437-43.
67. Chaieb K, Zmantar T, Ksouri R, Hajlaoui H, Mahdouani K, Abdelly C, *et al.* Antioxidant properties of the essential oil of *Eugenia caryophyllata* and its antifungal activity against a large number of clinical *Candida* species. *Mycoses* 2007;50:403-6.
68. Chami N, Bennis S, Chami F, Aboussekhra A, Remmal A. Study of anticandidal activity of carvacrol and eugenol *in vitro* and *in vivo*. *Oral Microbiol Immunol* 2005;20:106-11.
69. Khan MS, Malik A, Ahmad I. Anti-candidal activity of essential oils alone and in combination with amphotericin B or fluconazole against multi-drug resistant isolates of *Candida albicans*. *Med Mycol* 2012;50:33-42.
70. Tampieri MP, Galuppi R, Macchioni F, Carelle MS, Falcioni L, Cioni PL, Morelli I. The inhibition of *Candida albicans* by selected essential oils and their major components. *Mycopathologia* 2005;159:339-45.
71. Núñez L, D'Aquino M, Chirife J. Antifungal properties of clove oil (*Eugenia caryophyllata*) in sugar solution. *Braz J Microbiol* 2001; 32: 123-6.
72. Gayoso CW, Lima EO, Oliveira VT, Pereira FO, Souza EL, Lima IO, *et al.* Sensitivity of fungi isolated from *onychomycosis* to *Eugenia caryophyllata* essential oil and eugenol. *Fitoterapia* 2005;76:247-9.
73. Chami F, Chami N, Bennis S, Bouchikhi T, Remmal A. Oregano and clove essential oils induce surface alteration of *Saccharomyces cerevisiae*. *Phytother Res* 2005; 19: 405-8.
74. Lopez P, Sanchez C, Batlle R, Nerin C. Solid- and vapor-phase antimicrobial activities of six essential oils: susceptibility of selected foodborne bacterial and fungal strains. *J Agric Food Chem* 2005; 53: 6939-46.
75. Pawar VC, Thaker VS. *In vitro* efficacy of 75 essential oils against *Aspergillus niger*. *Mycoses* 2006; 49: 316 -23.
76. Pinto E, Vale-Silva L, Cavaleiro C, Salgueiro L. Antifungal activity of the clove essential oil from *Syzygium aromaticum* on *Candida*, *Aspergillus* and dermatophyte species. *J Med Microbiol* 2009;58:1454-62.
77. He M, Du M, Fan M, Bian Z. *In vitro* activity of eugenol against *Candida albicans* biofilms. *Mycopathologia* 2007;163:137-43.
78. Garg A, Singh S. Enhancement in antifungal activity of eugenol in immunosuppressed rats through lipid nanocarriers. *Colloid Surface B* 2011; 87: 280-8.
79. Marcos-Arias C, Eraso E, Madariaga L, Quindós G. *In vitro* activities of natural products against oral *Candida* isolates from denture wearers. *BMC Complement Altern Med* 2011;11:119-21.
80. Benecia F, Courrges MC. *In vitro* and *in vivo* activity of eugenol on human herpesvirus. *Phytother. Res* 2000; 14: 495-500.
81. Tragoolpua Y, Jatisatienr A. Anti-herpes simplex virus activities of *Eugenia caryophyllus* (Spreng.) (Bullock & S. G. Harrison) and essential oil, eugenol. *Phytother Res* 2007; 21: 1153-8.
82. Hussein G, Miyashiro H, Nakamura N, Hattori M, Kakiuchi N, Shimotohno K. Inhibitory effects of Sudanese medical plant extracts on hepatitis C virus (HCV) protease. *Phytother Res* 2000; 14: 510-16.
83. Daniel AN, Sartoretto SM, Schmidt G, Caparroz-Assef SM, Bersani-Amado CA, Cuman RKN. Anti-inflammatory and antinociceptive activities of eugenol essential oil in experimental animal models. *Rev Bras Farmacogn*. 2009; 19: 212-7.
84. Kurian R, Arulmozhi DK., Veeranjanyulu A, Bodhankar SL. Effect of eugenol on animal models of nociception. *Indian J. Pharmacol* 2006; 38: 341-5.
85. Guenette SA, Beaudry F, Marier JF, Vachon P. Pharmacokinetics and anesthetic activity of eugenol in male Sprague-Dawley rats. *J Vet Pharmacol Ther* 2006;29:265-70.
86. Keene JL, Noakes DLG, Moccia RD, Soto CG. The efficacy of clove oil as an anaesthetic for rainbow trout, *Oncorhynchus mykiss* (Walbaum). *Aquacult Res* 1998; 29: 89-101.
87. Rapp C. Clove oil as effective as topical anesthetic. *Herbal Gram* 2007; 74: 26.
88. Markowitz K, Moynihan M, Liu M, Kim S. Biologic properties of eugenol and zinc oxide-eugenol. A clinically oriented review. *Oral Surg Oral Med Oral Pathol* 1992; 73: 729- 37.
89. Kaur G, Athar M, Alam MS. Eugenol precludes cutaneous chemical carcinogenesis in mouse by preventing oxidative stress and inflammation and by inducing apoptosis. *Molecular Carcinogenesis* 2010; 49: 290-301.
90. Manach C, Mazur A, Scalbert A. Polyphenols and prevention of cardiovascular diseases. *Curr Opin Lipidol* 2005;16:77-84.
91. Auclair S, Silberberg M, Gueux E, Morand C, Mazur A, Milenkovic D, Scalbert A.J. Apple polyphenols and fibers attenuate atherosclerosis in apolipoprotein E-deficient mice. *Agric Food Chem* 2008 ;56:5558-63.
92. Scalbert A, Manach C, Morand C, Rémésy C, Jiménez L. Dietary polyphenols and the prevention of diseases. *Crit Rev Food Sci Nutr* 2005;45:287-306.
93. Criddle DN, Madeira SV, Soares de Moura R. Endothelium-dependent and -independent vasodilator effects of eugenol in the rat mesenteric vascular bed. *J Pharm Pharmacol* 003;55:359-65.
94. Sensch O, Vierling W, Brandt W, Reiter M. Effects of inhibition of calcium and potassium currents in guinea-pig cardiac contraction: comparison of beta-caryophyllene oxide, eugenol, and nifedipine. *Br J Pharmacol* 2000; 131:1089-96.
95. Damiani CE, Rossoni LV, Vassallo DV. Vasorelaxant effects of eugenol on rat thoracic aorta. *Vascul Pharmacol* 2003; 40:59-66.
96. Karmakar S, Choudhury M, Das AS, Maiti A, Majumdar S, Mitra C. Clove (*Syzygium aromaticum* Linn) extract rich in eugenol and eugenol derivatives shows bone-preserving efficacy. *Nat Prod Res* 2012; 26:500-9.
97. Sarrami N, Pemberton MN, Thornhill MH, Theaker ED. Adverse reactions associated with the use of eugenol in dentistry. *Brit Dent J* 2002; 193: 257-9.